RANI THERAP.H. A DL-,0001 Aktie

Rani Therapeutics showcased its RaniPill, an ingestible capsule that injects biologics into the small intestine and, according to management, can deliver monoclonal antibodies and large proteins orally. Lead program RT-114 showed a relative bioavailability of over 150% versus subcutaneous dosing in Phase I-A; additional RT-114 data are expected in H1 2025. The company highlights a strategic partnership with Chugai (potential value ~USD 1 billion plus options) and a PIPE financing, and reports USD 53 million in liquidity, which it says should fund operations through the end of 2027. Rani is expanding automated manufacturing capacity (first line 1,500 capsules/day, target 10,000/day) but continues to note typical biotech risks in execution, production and subsequent proof of efficacy. » Mais em de.investing.com

Rani Therapeutics showcased its RaniPill platform at the Canaccord Growth Conference, saying it can deliver 80–85% of typical market biologics orally with subcutaneous-like bioavailability. The company highlighted a $1 billion partnership with Chugai as validation and reported that RT-114 achieved a relative bioavailability of over 150% versus subcutaneous dosing in Phase I-a. Rani has $43 million in cash and marketable securities, expected to last through Q4 2027, and is pursuing partnerships rather than building its own salesforce; production lines for various indications are being ramped up. Management cites scaling costs, partner dependence and strong competition in the obesity market as the main risks. » Mais em de.investing.com

Rani Therapeutics reports positive results from a Phase‑1a single‑dose study of RT-114, a RaniPill‑delivered capsule containing the GLP‑1/GLP‑2 dual agonist PG‑102. In 30 healthy volunteers, oral dosing produced more than 150% higher systemic exposure than subcutaneous injection; there were no serious adverse events and no capsule‑related adverse events. Half‑life was 5.6 days versus 5.3 days. The company is expanding the study by 15 additional subjects with repeated dosing to identify a dose for a planned Phase‑1b in obese patients, with the trial expected to start in 2026 and first data anticipated in 2027. Development is happening in partnership with ProGen, with costs and revenues split 50:50; the stock has fallen sharply year to date. » Mais em de.investing.com